The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

Acorda Announces Patent Trials and Appeal Board Denies Both IPRs of AMPYRA Patents

25-Aug-2015 | Source : Acorda Therapeutics | Visits : 5862
ARDSLEY, N.Y. - Acorda Therapeutics Inc. announced in a press release that the United States Patent and Trademark Office (USPTO) Patent Trials and Appeal Board (PTAB) will not institute the inter partes review (IPR) of US Patent Nos. 8,663,685 (“the '685 patent”) and 8,007,826 (“the '826 patent”).

The '685 and '826 patents are two of five Orange Book-listed patents that apply to AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, a novel treatment for multiple sclerosis (“MS”) developed by Acorda. AMPYRA is a standard of care for improving walking in MS. The '685 and '826 patents are set to expire in 2025 and 2027, respectively.

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders.

Related Articles